Serum Lactate and Ulcerative Colitis
Serum Lactate and Mean Platelet Volume as Predicators for Acute Exacerbation in Patients With Ulcerative Colitis
1 other identifier
observational
137
1 country
1
Brief Summary
Patients presenting with severe symptoms of ulcerative colitis (UC) require hospital admission for urgent assessment and therapy. Endoscopic examination of the rectum and/or distal colon is often performed to assess severity and obtain tissue for histopathologic evaluation, but this is often extended to full colonoscopy to assess the extent of bowel involvement. Full colonoscopy is hazardous in this setting
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 7, 2023
CompletedFirst Posted
Study publicly available on registry
May 25, 2023
CompletedStudy Start
First participant enrolled
June 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJuly 20, 2023
July 1, 2023
7 months
May 7, 2023
July 18, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Accuracy (%) of serum lactate in prediction the acute flare of ulcerative colitis
By using the receiver operator characteristics curve, we can determine the best cutoff point of serum lactate to predict the acute flare of ulcerative colitis
one year
Study Arms (1)
patients with ulcerative colitis
any patients with ulcerative colitis
Interventions
assessment of serum lactate and mean platelets volume
Eligibility Criteria
Any patient who is above age of 18 years old and diagnosed to have UC based on combination between clinical, laboratory, radiological, endoscopic and/or histopathological data whatever the course of the disease
You may not qualify if:
- Patients with inflammatory bowel disease (IBD) other than UC as those with Crohn's disease or microscopic colitis
- Pregnant patients with ulcerative colitis.
- Patients with UC who are under age of 18 years old
- Patient's refusal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ahmed Mohammed Abu-Elfatth
Asyut, 71515, Egypt
Related Publications (1)
Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231.
PMID: 24696607BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ahmed M Abu-Elfatth
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of Tropical Medicine and Gastroenterology
Study Record Dates
First Submitted
May 7, 2023
First Posted
May 25, 2023
Study Start
June 1, 2023
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
July 20, 2023
Record last verified: 2023-07